Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A-Reference-Cited by-同舟云学术

Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A

Published:2020-06-05 Issue:12 Volume:59 Page:1611-1625
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Retout Sylvie^ORCID,Schmitt Christophe,Petry Claire,Mercier François,Frey Nicolas

Funder

F. Hoffman-La Roche Ltd

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40262-020-00904-z.pdf

Reference41 articles.

1. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535–44. https://doi.org/10.1056/NEJMoa067659.

2. Ljung R. The risk associated with indwelling catheters in children with haemophilia. Br J Haematol. 2007;138(5):580–6. https://doi.org/10.1111/j.1365-2141.2007.06703.x.

3. Franchini M, Tagliaferri A, Mengoli C, Cruciani M. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review. Crit Rev Oncol Hematol. 2012;81(1):82–93. https://doi.org/10.1016/j.critrevonc.2011.01.002.

4. Leissinger CA, Konkle BA, Antunes SV. Prevention of bleeding in hemophilia patients with high-titer inhibitors. Expert Rev Hematol. 2015;8(3):375–82. https://doi.org/10.1586/17474086.2015.1036733.

5. Konkle BA, Ebbesen LS, Erhardtsen E, Bianco RP, Lissitchkov T, Rusen L, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost. 2007;5(9):1904–13. https://doi.org/10.1111/j.1538-7836.2007.02663.x.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A;Haemophilia;2024-04-29

2. Impact of covariate model building methods on their clinical relevance evaluation in population pharmacokinetic analyses: comparison of the full model, stepwise covariate model (SCM) and SCM+ approaches;Journal of Pharmacokinetics and Pharmacodynamics;2024-04-09

3. Lower-dose emicizumab prophylaxis: can less be more?;Journal of Thrombosis and Haemostasis;2024-04

4. Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks;Research and Practice in Thrombosis and Haemostasis;2024-01

5. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial;Blood Journal;2023-12-21